Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Warner-admin (talk | contribs) m (Text replacement - "[[Neuroendocrine tumors" to "[[Neuroendocrine tumor") |
m |
||
| Line 9: | Line 9: | ||
*[[Chronic myelogenous leukemia]] | *[[Chronic myelogenous leukemia]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| + | *[[Hairy cell leukemia]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Neuroendocrine tumor]] | *[[Neuroendocrine tumor]] | ||
| Line 35: | Line 36: | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Hairy cell leukemia medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
Revision as of 14:44, 14 September 2019
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Follicular lymphoma
- Hairy cell leukemia
- Melanoma
- Neuroendocrine tumor
- Renal cell carcinoma
- Cutaneous squamous cell carcinoma
Diseases for which it was used
Patient drug information
History of changes in FDA indication
- 6/4/1986: Initial FDA approval
Also known as
- Brand name: Roferon-A